PER® Winter Lung Cancer Conference | Conference

Dr. Wakelee on Immediate Therapy Options in Lung Cancer

February 10th 2020

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

Dr. Pennell on Benefits of Liquid Biopsies in Lung Cancer

February 10th 2020

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.

Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC

February 10th 2020

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

Should EGFR TKI Use Expand in Frontline NSCLC?

February 10th 2020

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.

Therapeutic Advances Promote Personalized Medicine in Advanced NSCLC

February 10th 2020

Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.

Finding the Immunotherapy Finish Line Remains a Challenge in NSCLC

February 9th 2020

Based on available data, treatment is not that obvious for patients with metastatic non–small cell lung cancer who are tolerating treatment well and have either a complete or partial response to therapy.

Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer

February 9th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer

February 9th 2020

Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.

Immunotherapy Restructures the SCLC Treatment Landscape

February 9th 2020

The standard of care for patients with small cell lung cancer has been trapped in a period of stagnation for the past several decades.

Optimal Immunotherapy Sequencing Remains Elusive in Lung Cancer

February 9th 2020

The potential therapeutic benefits of immune checkpoint inhibitors as monotherapy as well as in combination with chemotherapy for patients with non–small cell lung cancer depend greatly on the timing of treatment initiation. However, for patients with EGFR, ALK, and other actionable mutations, identifying the optimal combination is a hurdle.

Building on Momentum Is Vital in Lung Cancer

February 8th 2020

Advancements in the prevention and treatment of patients with lung cancer have picked up momentum over the past decade and now is the time to build on that progress according to Suresh S. Ramalingam, MD, FASCO.

Dr. Chaft on the Rise of Immunotherapy in Lung Cancer

February 8th 2020

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.

Dr. Lilenbaum on PD-L1 as a Predictive Biomarker for Immunotherapy in Lung Cancer

February 8th 2020

Rogerio C. Lilenbaum, MD, discusses using PD-L1 as a predictive biomarker for immunotherapy and the search for additional biomarkers in lung cancer.

Emerging Targeted Therapies Emphasize Need for Molecular Testing in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

Using TMB and PD-L1 Together Could Guide Immunotherapy Decisions in NSCLC

January 29th 2019

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.

Socinski Says Immunotherapy, Targeted Therapy Have Altered Outlook in NSCLC

January 29th 2019

Mark A. Socinski, MD, provides an overview of treatment advances in the lung cancer landscape, and highlights where much-needed work still remains.

Expert Stresses Significance of Durvalumab Success in Stage III NSCLC

January 28th 2019

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

Dr. Decker on Current Role of Radiation in NSCLC

January 28th 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non–small cell lung cancer.

Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC

January 28th 2019

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Dr. Jahanzeb on Eligibility Criteria for Immunotherapy Trials in NSCLC

January 28th 2019

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non–small cell lung cancer.